Drugs / MagniXene

Trials 2

2012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT01833390 Sep 2011 → Jan 2015 asthma, chronic obstructive pulmonary disease Xemed LLC Completed No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT01832363 Mar 2013 → Dec 2018 asthma Xemed LLC Completed No outcome recorded

News releases announcing trial results or a regulatory action · 2

DateIssuerRelease
2018-06-01 Xemed LLC Results Scientific Reports publishes article describing a method for assessing pulmonary gas transport using MagniXene® xemed.com ↗
The technique is unique in providing critical information on the xenon exchange dynamics, which follows a pathway similar to that of oxygen.
2011-08-01 Xemed LLC Regulatory Xemed completes regulatory filings with Health Canada xemed.com ↗
Earlier in the summer, Xemed had submitted a “Drug Master File” on MagniXene™ to Health Canada to begin the two-step regulatory filing process.

All press releases naming this drug 2 releases

DateIssuerRelease

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as MagniXene “MagniXene® is pure xenon gas which is magnetically altered to become a contrast agent for magnetic resonance imaging of the lungs.” NCT01832363 ↗
1

“MagniXene (HXe) is an Investigational New Drug made of xenon noble gas.” NCT01833390 ↗

Modality Diagnostic / imaging agent “contrast agent for magnetic resonance imaging of the lungs” NCT01832363 ↗
Route Inhaled “The subject inhales the hyperpolarized xenon while inside the MRI scanner” NCT01832363 ↗